Thomas L. Blundell
Director/Board Member at Science Foundation Ireland
Profile
Thomas L.
Blundell was the founder of Astex Therapeutics Ltd.
founded in 1999, where he held the title of Director from 1999 to 2011.
He is currently the Director at Science Foundation Ireland.
In the past, he held the position of Chief Executive Officer at Biotechnology & Biological Sciences Research Council from 1994 to 1996 and was the Head of Biochemistry Department at the University of Cambridge.
Thomas L. Blundell active positions
| Companies | Position | Start |
|---|---|---|
Science Foundation Ireland
 Science Foundation Ireland Miscellaneous Commercial ServicesCommercial Services Science Foundation Ireland funds oriented basic and applied research in the areas of science, technology, engineering, and mathematics (STEM). It promotes and supports the study of, education in, and engagement with STEM and promotes an awareness and understanding of the value of STEM to society. The company was founded in 1998 and is headquartered in Dublin, Ireland,. | Director/Board Member | - |
Former positions of Thomas L. Blundell
| Companies | Position | End |
|---|---|---|
Biotechnology & Biological Sciences Research Council
 Biotechnology & Biological Sciences Research Council Miscellaneous Commercial ServicesCommercial Services Biotechnology & Biological Sciences Research Council operates a funding agency for academic research and training. It funds bioscience, people and research infrastructure that helps to tackle major challenges such as the impact of climate change, a healthier old age, and sustainable food production, land use and energy production. The company is headquartered in Swindon, the United Kingdom. | President | 31/12/1995 |
| University of Cambridge | Corporate Officer/Principal | - |
Astex Therapeutics Ltd.
 Astex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Astex Therapeutics Ltd. engages in the provision of drug discovery and development activities. Its proprietary fragment-based drug discovery platform, Pyramid, delivers drug leads on therapeutic targets and disease areas.The company was founded by Harren Jhotin, Roberto Solari, Stephen W. Bunting, Christopher Abell, and Thomas L. Blundell in 1999 and is headquartered in Cambridge, the United Kingdom. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Astex Therapeutics Ltd.
Astex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Astex Therapeutics Ltd. engages in the provision of drug discovery and development activities. Its proprietary fragment-based drug discovery platform, Pyramid, delivers drug leads on therapeutic targets and disease areas.The company was founded by Harren Jhotin, Roberto Solari, Stephen W. Bunting, Christopher Abell, and Thomas L. Blundell in 1999 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Biotechnology & Biological Sciences Research Council
Biotechnology & Biological Sciences Research Council Miscellaneous Commercial ServicesCommercial Services Biotechnology & Biological Sciences Research Council operates a funding agency for academic research and training. It funds bioscience, people and research infrastructure that helps to tackle major challenges such as the impact of climate change, a healthier old age, and sustainable food production, land use and energy production. The company is headquartered in Swindon, the United Kingdom. | Commercial Services |
Science Foundation Ireland
Science Foundation Ireland Miscellaneous Commercial ServicesCommercial Services Science Foundation Ireland funds oriented basic and applied research in the areas of science, technology, engineering, and mathematics (STEM). It promotes and supports the study of, education in, and engagement with STEM and promotes an awareness and understanding of the value of STEM to society. The company was founded in 1998 and is headquartered in Dublin, Ireland,. | Commercial Services |
- Stock Market
- Insiders
- Thomas L. Blundell